No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.

Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.

[1]  N. White,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine , 1999 .

[2]  N. White,et al.  Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. , 1999, The American journal of tropical medicine and hygiene.

[3]  R. Price,et al.  Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. , 1999, The American journal of tropical medicine and hygiene.

[4]  M Malik,et al.  Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion. , 1998, The American journal of cardiology.

[5]  Morrison Hodges,et al.  Rate Correction of the QT Interval , 1997 .

[6]  R. Price,et al.  Prolongation of the QTc interval in African children treated for falciparum malaria. , 1997, The American journal of tropical medicine and hygiene.

[7]  N. White,et al.  A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. , 1996, The New England journal of medicine.

[8]  M. Zeng,et al.  Determination of benflumetol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. , 1996, Journal of chromatography. B, Biomedical applications.

[9]  A. Viguier,et al.  Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. , 1996, The American journal of tropical medicine and hygiene.

[10]  S. Luby,et al.  Cardiac effects of standard-dose halofantrine therapy. , 1996, The American journal of tropical medicine and hygiene.

[11]  N. White,et al.  Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. , 1994, The Journal of infectious diseases.

[12]  S. Grate,et al.  Fatal neurotoxicity of arteether and artemether. , 1994, The American journal of tropical medicine and hygiene.

[13]  D. Kyle,et al.  Cardiac effects of antimalarial treatment with halofantrine , 1993, The Lancet.

[14]  N. White,et al.  Quinine and Quinidine: A Comparison of EKG Effects During the Treatment of Malaria , 1983, Journal of cardiovascular pharmacology.

[15]  Clyde Df.  Treatment of multi-drug resistant malaria. , 1967 .

[16]  G. Edwards,et al.  Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation. , 1997, Scandinavian journal of infectious diseases.

[17]  S. Jaffar,et al.  Prolongation of the QTc interval in African children treated for falciparum malaria. , 1997, The American journal of tropical medicine and hygiene.